We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Merck & Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Vaxneuvance 15-valent pneumococcal vaccine in adults.
The Kenilworth, N.J., drugmaker said the recommendation covers Vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
The European Commission, which generally follows the CHMP's advice, will now review the recommendations, with decisions expected by the end of the year.
The U.S. Food and Drug Administration earlier this year approved Vaxneuvance for adults.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 15, 2021 08:13 ET (12:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
